An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination

BACKGROUND: Current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and extramedullar sites. We developed a protein-based nanoparticle conjugated to the p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hematol Oncol
Autori principali: Pallarès, Victor, Unzueta, Ugutz, Falgàs, Aïda, Sánchez-García, Laura, Serna, Naroa, Gallardo, Alberto, Morris, Gordon A., Alba-Castellón, Lorena, Álamo, Patricia, Sierra, Jorge, Villaverde, Antonio, Vázquez, Esther, Casanova, Isolda, Mangues, Ramon
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160905/
https://ncbi.nlm.nih.gov/pubmed/32295630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00863-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi